Gastrointestinal Cancers Recommendations
To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.
If you think you should be able to access this content, please contact us.
New to F1000? See this week’s top article below for a free preview of a Recommendation.
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Klinik fur Innere Med IV, University Clinic Halle, Halle/Saale, Germany
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Department of Histopathology, Cancer Research UK, London, UK
- » Colorectum
- » Esophagus
- » Familial syndromes
- » Gall bladder and biliary tract
- » Gastrointestinal cancer: chemoprevention
- » Gastrointestinal cancer: chemotherapy
- » Gastrointestinal cancer: surgery
- » Liver
- » Pancreas
- » Small intestine
- » Stomach
Sorafenib has been shown to improve survival in patients with hepatocellular carcinoma (HCC). This study evaluated whether sorafenib at a higher dose (600mg bis in die [BID]) in patients who experienced radiologic disease...
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
3 Recommendations, most recent by
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.